Deviation – Page 155

Control Strategy Weakness for long-acting injectables: regulatory-ready investigation and CAPA plan

Investigation into Control Strategy Weaknesses for Long-Acting Injectables: A Regulatory-Ready Approach In the landscape of pharmaceutical manufacturing, control strategy weaknesses can disrupt the quality and efficacy of long-acting injectables, potentially…

API melting point / DSC anomaly during EU GMP inspection preparation: control strategy updates for CPPs/CMAs and continued process verification

Identifying and Addressing API Melting Point DSC Anomalies in EU GMP Inspection Preparation Pharmaceutical manufacturing is susceptible to various anomalies that can affect product quality. One such issue is the…

Ph Drift during method transfer: manufacturing vs lab root cause decision tree

Understanding pH Drift During Method Transfer: A Root Cause Investigation Framework In pharmaceutical manufacturing, one critical issue that can arise during method transfer is pH drift. This phenomenon can lead…

Crimp Diameter Variability at stability pull: FDA/MHRA inspection-ready documentation

Understanding Crimp Diameter Variability During Stability Pulls: An Investigation Framework Crimp diameter variability during stability pulls can pose significant challenges in pharmaceutical manufacturing, particularly for aerosol formulations. Variability in crimp…

Spray Pattern Failure in MDI assembly: FDA/MHRA inspection-ready documentation

Addressing Spray Pattern Failures in MDI Assembly: An Investigation Framework Within the pharmaceutical manufacturing landscape, especially in the realm of metered-dose inhalers (MDIs), ensuring consistent spray patterns is crucial for…

API photostability failure after equipment maintenance intervention: control strategy updates for CPPs/CMAs and continued process verification

Control Strategy Updates Following API Photostability Failure After Equipment Maintenance Intervention In the pharmaceutical manufacturing landscape, maintaining strict compliance with Good Manufacturing Practices (GMP) is essential for ensuring product quality…

Microbial Limits Failure during line setup: GMP documentation for FDA/EMA/MHRA review

Addressing Microbial Limits Failures during Line Setup: A Comprehensive Investigation Guide In the pharmaceutical manufacturing sector, regulatory compliance is paramount, particularly when addressing microbial limits during line setups. A microbial…

Pressure Loss during line setup: packaging integrity and transport risk assessment

Assessing Pressure Loss during Line Setup: A Comprehensive Investigation Approach In pharmaceutical manufacturing, especially in the realm of aerosol formulations, maintaining the integrity of product packaging while ensuring safe transport…

E&L Failure in MDI assembly: method variability vs true product failure assessment

Assessment of E&L Failures in MDI Assembly: Evaluating Method Variability vs True Product Failure In the context of pharmaceutical manufacturing, particularly with Metered Dose Inhalers (MDIs), the occurrence of extractables…

Net Content Failure during inspection readiness: packaging integrity and transport risk assessment

Addressing Net Content Failure During Inspection Readiness: A Practical Investigation Framework Net content failure is a significant concern in pharmaceutical manufacturing, particularly during inspection readiness periods. This issue can lead…

API impurity profile OOS after cleaning validation requalification: data integrity and chromatographic audit trail review steps

Investigating OOS Results for API Impurity Profiles Post-Cleaning Validation Requalification In the pharmaceutical manufacturing environment, the integrity and reliability of active pharmaceutical ingredient (API) impurity profiles are paramount. A recent…

Microbial Limits Failure after supplier change: GMP documentation for FDA/EMA/MHRA review

Understanding Microbial Limits Failure Following a Supplier Change in Pharmaceutical Manufacturing In the pharmaceutical manufacturing landscape, deviations related to microbial limits can pose significant compliance challenges, especially after a change…